Investing.com - Adaptimmune Therapeutics reported on Thursday first quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Adaptimmune Therapeutics announced earnings per share of $-0.04 on revenue of $0.43M. Analysts polled by Investing.com anticipated EPS of $-0.25 on revenue of $700K.
Adaptimmune Therapeutics shares are down 5% from the beginning of the year and are trading at $5.12 , down-from-52-week-high.They are under-performing the STOXX 600 which is up 10.28% from the start of the year.
Adaptimmune Therapeutics follows other major Healthcare sector earnings this month
Adaptimmune Therapeutics's report follows an earnings beat by J&J on April 20, who reported EPS of $2.59 on revenue of $22.32B, compared to forecasts EPS of $2.34 on revenue of $21.98B.
Pfizer had beat expectations on Tuesday with first quarter EPS of $0.93 on revenue of $14.58B, compared to forecast for EPS of $0.7773 on revenue of $13.67B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar